SCHEMBL6488752

SCHEMBL6488752

O=S(=O)(CCc1ccccc1)NS(=O)(=O)CCc1ccccc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 1/20 0.63
MMP8 P22894 3/20 0.56
MMP13 P45452 3/20 0.56
MMP12 P39900 2/20 0.56
MMP1 P03956 2/20 0.56
MMP7 P09237 1/20 0.56
PTGES2 Q9H7Z7 1/20 0.54
CA2 P00918 4/20 0.52
GLO1 Q04760 1/20 0.47
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
KDM4E B2RXH2 1/20 0.47
ALDH1A1 P00352 1/20 0.47
LMNA P02545 1/20 0.47
CYP3A4 P08684 1/20 0.47
GAA P10253 1/20 0.47
MAPT P10636 1/20 0.47
BLM P54132 1/20 0.47
GFER P55789 1/20 0.47
PMP22 Q01453 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6491355 0.87 CA2 (0.55) IDO1MMP8MMP13MMP12MMP1
SCHEMBL6793104 0.83 IDO1 (0.59) IDO1MMP8MMP13MMP12MMP1
SCHEMBL8987446 0.83 IDO1 (0.59) IDO1MMP8MMP13MMP12MMP1
SCHEMBL16914880 0.83 MMP8 (0.64) IDO1MMP8MMP13MMP12MMP1
SCHEMBL10890460 0.83 IDO1 (0.59) IDO1MMP8MMP13MMP12MMP1
SCHEMBL15754219 0.81 L3MBTL1 (0.64) IDO1MMP8MMP13MMP12MMP1
SCHEMBL15622087 0.81 IDO1 (0.68) IDO1MMP8MMP13MMP12MMP1
SCHEMBL426660 0.79 IDO1 (0.56) IDO1MMP8MMP13MMP12MMP1
SCHEMBL426661 0.79 IDO1 (0.56) IDO1MMP8MMP13MMP12MMP1
SCHEMBL3836194 0.79 MMP8 (0.58) IDO1MMP8MMP13MMP12MMP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors DAISO CO., LTD. (JP) 2005-02-17 US disclosed
US-20040058903-A1 Benzamide compounds as apo b secretion inhibitors FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-03-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040058903-A1 Benzamide compounds as apo b secretion inhibitors APOB, APOL1, SCARB1 IDO1 696/4885MMP8 1358/4885MMP13 2294/4885
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors APOB, APOL1, CTRB2 IDO1 246/4885MMP8 1156/4885MMP13 1599/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.